# LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

> **NCT04391595** · EARLY_PHASE1 · COMPLETED · sponsor: **Nader Sanai** · enrollment: 42 (actual)

## Conditions studied

- Glioblastoma
- GBM
- Glioma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** LY3214996

## Key facts

- **NCT ID:** NCT04391595
- **Lead sponsor:** Nader Sanai
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-11
- **Primary completion:** 2023-07-27
- **Final completion:** 2025-09-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04391595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04391595, "LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04391595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*